Health
Combination immunotherapy benefits subset of patients with advanced prostate cancer. – Brinkwire
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), an “immune-cold” cancer that does not typically respond well to immunotherapy.
In a cohort of patients without previous chemotherapy treatment, the overall response rate (ORR) was 25% and median ove…
Continue Reading
-
General23 hours agoDonald Trump’s initial 10 per cent tariff takes effect
-
General22 hours agoJaguar Land Rover in UK pauses shipments to US
-
General19 hours agoTexas opens probe into Kellogg’s health claims, dyes
-
General18 hours agoAustralian share market set to dive as threat of US recession grows